Suga Kazuyoshi, Kawakami Yasuhiko, Hiyama Atsuto, Matsunaga Naofumi
Department of Radiology, St. Hill Hospital, 1462-3 Nishikiwa, Ube, Yamaguchi, 755-0151, Japan.
Ann Nucl Med. 2009 Jun;23(4):399-407. doi: 10.1007/s12149-009-0261-5. Epub 2009 May 20.
To evaluate the ability of dual-time point F-18-fluorodeoxy-glucose (FDG) PET/CT scans to differentiate FDG-avid loco-regional recurrent and compromised benign lesions after surgery for breast cancer.
A total of 64 FDG-avid recurrent lesions (local tumor recurrence or lymph node metastases) in 52 patients and 38 FDG-avid compromised benign lesions after surgery in 37 patients were included in the study. FDG PET/CT study was performed at 60 and 120 min after intravenous injection of 3.5 MBq/kg FDG. The maximum SUV (SUVmax) on the early and delayed scans and the percent change of SUVmax (%DeltaSUVmax) between the two time points were measured. The optimal differential parameter was determined by receiver-operating characteristic curve analysis.
The average early SUVmax, delayed SUVmax and DeltaSUVmax% were 4.9 +/- 2.6, 6.0 +/- 3.6 and 18.2% +/- 18.8 in FDG-avid recurrent lesions, and 2.1 +/- 0.8, 1.8 +/- 1.0 and -17.8% +/- 21.3 in FDG-avid benign lesions, respectively. Delayed SUVmax was significantly increased compared with early SUVmax in recurrent lesions (P < 0.0001), while it was decreased in benign lesions (P < 0.0001). All the three parameters in recurrent lesions were significantly higher than those in benign lesions (P < 0.0001). The highest diagnostic accuracy of the differentiation was achieved by the combined use of the optimal parameter of delayed SUVmax > 2.5 and %DeltaSUVmax > 0%, with a sensitivity of 90.6%, specificity of 81.5%, accuracy of 87.2%, NPV of 89.2%, and PPV of 83.7%, which were better than the respective values obtained with the use of delayed SUVmax > 2.5 alone or %DeltaSUVmax > 0% alone (P < 0.005 and P < 0.05, respectively), and the use of the traditional parameter of early SUVmax > 2.5 (P < 0.005).
This approach with SUVmax estimation appears to improve the differentiation between FDG-avid loco-regional recurrent of breast cancer and compromised benign lesions after surgery, since delayed scanning significantly enhances the difference in FDG uptake between these lesions.
评估双时相F-18-氟脱氧葡萄糖(FDG)PET/CT扫描鉴别乳腺癌术后FDG摄取阳性的局部区域复发病灶和良性病变的能力。
本研究纳入了52例患者中的64个FDG摄取阳性的复发病灶(局部肿瘤复发或淋巴结转移)以及37例患者术后的38个FDG摄取阳性的良性病变。静脉注射3.5 MBq/kg FDG后60分钟和120分钟进行FDG PET/CT检查。测量早期和延迟扫描的最大SUV(SUVmax)以及两个时间点之间SUVmax的变化百分比(%DeltaSUVmax)。通过受试者操作特征曲线分析确定最佳鉴别参数。
FDG摄取阳性的复发病灶的平均早期SUVmax、延迟SUVmax和DeltaSUVmax%分别为4.9±2.6、6.0±3.6和18.2%±18.8,而FDG摄取阳性的良性病变分别为2.1±0.8、1.8±1.0和-17.8%±21.3。复发病灶中延迟SUVmax较早期SUVmax显著升高(P<0.0001),而良性病变中延迟SUVmax降低(P<0.0001)。复发病灶的所有三个参数均显著高于良性病变(P<0.0001)。联合使用延迟SUVmax>2.5和%DeltaSUVmax>0%的最佳参数时,鉴别诊断的准确性最高,敏感性为90.6%,特异性为81.5%,准确性为87.2%,阴性预测值为89.2%,阳性预测值为83.7%,优于单独使用延迟SUVmax>2.5或单独使用%DeltaSUVmax>0%时各自获得的值(分别为P<0.005和P<0.05),也优于使用早期SUVmax>2.5的传统参数(P<0.005)。
这种基于SUVmax评估的方法似乎可以改善乳腺癌术后FDG摄取阳性的局部区域复发病灶与良性病变之间的鉴别,因为延迟扫描显著增强了这些病变之间FDG摄取的差异。